The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Biosimilars in Pharmaceuticals: Hormone-based therapies for metabolic disorders.

According to GlobalData’s Technology Foresights, which uses over 756,000 patents to analyse innovation intensity for the pharmaceutical industry, there are 110 innovation areas that will shape the future of the industry.

Hormone-based therapies for metabolic disorders is a key innovation area in biosimilars

Hormone therapy, also called endocrine therapy, is the use of hormones as a therapeutic agent. Glucagon and insulin are the major hormonal therapies widely used for the treatment of various metabolic diseases such as type 2 diabetes mellitus, obesity, and hypoglycaemia.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 120+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of hormone-based therapies for metabolic disorders.

Key players in hormone-based therapies for metabolic disorders – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to hormone-based therapies for metabolic disorders

Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies
Novo Nordisk Foundation 1163 Unlock company profile
Hanmi Science 698 Unlock company profile
Eli Lilly and 646 Unlock company profile
Zealand Pharma 637 Unlock company profile
Merck & Co 317 Unlock company profile
AstraZeneca 218 Unlock company profile
Moderna 178 Unlock company profile
GSK 169 Unlock company profile
Ipsen 142 Unlock company profile
Sanofi 120 Unlock company profile
C. H. Boehringer Sohn 118 Unlock company profile
Amunix Operating 111 Unlock company profile
OPKO Health 102 Unlock company profile
Biocon 99 Unlock company profile
Alkermes 81 Unlock company profile
Intarcia Therapeutics 77 Unlock company profile
Mederis Diabetes 75 Unlock company profile
Jiangsu Hengrui Medicine 65 Unlock company profile
Pfizer 65 Unlock company profile
Gmax Biopharm 61 Unlock company profile
IP Group 53 Unlock company profile
Takeda Pharmaceutical 52 Unlock company profile
Amgen 49 Unlock company profile
BioAtla 46 Unlock company profile
F. Hoffmann-La Roche 46 Unlock company profile
MannKind 46 Unlock company profile
Akston Biosciences 41 Unlock company profile
Teva Pharmaceutical Industries 38 Unlock company profile
Jiangsu Haosen Pharmaceutical Group 37 Unlock company profile
Vectus Biosystems 37 Unlock company profile
Adocia 36 Unlock company profile
Zydus Lifesciences 36 Unlock company profile
PhaseBio Pharmaceuticals 33 Unlock company profile
Ferring Holding 33 Unlock company profile
CBL Patras 30 Unlock company profile
Ambrx Biopharma 29 Unlock company profile
Rubius Therapeutics 28 Unlock company profile
Life Sciences Research Partners VZW 26 Unlock company profile
ImCyse 25 Unlock company profile
Orgenesis 25 Unlock company profile
Ascendis Pharma 25 Unlock company profile
BrightGene Bio-Medical Technology 25 Unlock company profile
Shanghai Benemae Pharmaceutical 24 Unlock company profile
Boston Scientific 24 Unlock company profile
Sun Pharmaceutical Industries 23 Unlock company profile
Tel Hashomer Medical Research Infrastructure and Services 23 Unlock company profile
AngioChem 23 Unlock company profile
Genexine 22 Unlock company profile
D&D Pharmatech 21 Unlock company profile
HEC Pharm Group 21 Unlock company profile

Source: GlobalData Patent Analytics

Novo Nordisk is the top pharmaceutical company in metabolic diseases and the leading patent filer in hormone-based therapies. It has 20+ approved drugs and 40+ drugs under development for metabolic disorders. Hanmi Science and Eli Lilly are the other key patent filers in hormone-based therapies for metabolic disorders.

In terms of application diversity, Adocia is the top company, followed by Tel Hashomer Medical Research Infrastructure and Services and Orgenesis. By means of geographic reach, Rubius Therapeutics held the top position. Teva Pharmaceutical Industries and C. H. Boehringer Sohn stood in the second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.